Nicholas Bodor, Ph.D. |
Dr. Nicholas Bodor received his
B.S./M.S. degree in Organic Chemistry in 1959 at Babes - Bolyai University in Cluj
(Romania), and his Ph.D. degree in 1965 from the same university and the Romanian National
Academy of Sciences. He was a Group Leader at the Pharmacochemical Research Institute in
Romania until 1968, when he received a R. A. Welch Fellowship at the University of Texas
in Austin. After returning to Romania for one year, he received another R. A. Welch
Fellowship. In 1972 he became a Senior Research Scientist at ALZA Laboratories in
Lawrence, Kansas, which later became INTERx Research Corporation, where he was Director of
Research, as well as an Adjunct Professor at the University of Kansas until 1978. Dr. Bodor joined the University of Florida in Gainesville in 1979 as
Professor and Chairman of the Medicinal Chemistry Department. He was promoted to Graduate
Research Professor of the University in 1983. Currently, he has joint appointments in the
Departments of Pharmaceutics and Medicinal Chemistry, and is also the Executive Director
of the Center for Drug Discovery
(formerly the Center for Drug Design and Delivery) in the College of Pharmacy. In
addition, he is Affiliate Graduate Research Professor in the Department of Chemistry in
the College of Liberal Arts and the Department of Ophthalmology in the College of Medicine
at the University. During his tenure at the University of Florida, he has supervised the
training of 50 doctoral students and over 100 postdoctoral level research associates and
fellows.
Dr. Bodor's main research interests include design of drugs with
improved therapeutic index, design of new chemical delivery systems, computer-assisted
drug design, drug transport and metabolism, and theoretical and mechanistic organic
chemistry. He has published more than 450 research articles, has over 170 patents, and is
on the editorial boards of several international scientific journals. Dr. Bodor is the
founder and organizer of a biennial series of symposia entitled, The Retrometabolism
Based Drug Design and Targeting Conference, which is dedicated to the study of the
drug optimization strategies that he has pioneered. |
